Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer

Abstract

ID4 gene is a member of the inhibitor of DNA-binding (ID) family, which inhibits DNA binding of basic helix–loop–helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT–PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node-positive and seven of 36 (19%) node-negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P=0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P=0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Barth A, Craig PH and Silverstein MJ . (1997). Cancer, 79, 1918–1922.

  • Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR and Wong-Staal F . (2001). Proc. Natl. Acad. Sci. USA, 98, 130–135.

  • Benezra R, Rafii S and Lyden D . (2001). Oncogene, 20, 8334–8341.

  • Brenin DR, Manasseh DM, El-Tamer M, Troxel A, Schnabel F, Ditkoff BA and Kinne D . (2001). Ann. Surg. Oncol., 8, 432–437.

  • Carter BA, Jensen RA, Simpson JF and Page DL . (2000). Am. J. Clin. Pathol., 113, 259–265.

  • Carter CL, Allen C and Henson DE . (1989). Cancer, 63, 181–187.

  • Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Li R, So S, Yuen ST and Leung SY . (2003). Oncogene, 22, 6946–6953.

  • Esteller M and Herman JG . (2002). J. Pathol., 196, 1–7.

  • Fisher ER, Anderson S, Redmond C and Fisher B . (1993). Cancer, 71, 2507–2514.

  • Fisher ER, Fisher B, Sass R and Wickerham L . (1984). Cancer, 54, 3002–3011.

  • Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A and Schnitt SJ . (2000). Arch. Pathol. Lab. Med., 124, 966–978.

  • Herman JG and Baylin SB . (2003). N. Engl. J. Med., 349, 2042–2054.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Holland PA, Walls J, Boggis CR, Knox F, Baildam AD and Bundred NJ . (1996). Br. J. Cancer, 74, 1643–1646.

  • Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL and Taback B . (2004). Oncogene, 23, 4014–4022.

  • Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL and Desprez PY . (2003). Cancer Res., 63, 7098–7105.

  • Jen Y, Manova K and Benezra R . (1996). Dev. Dyn., 207, 235–252.

  • Jen Y, Manova K and Benezra R . (1997). Dev. Dyn., 208, 92–106.

  • Jones PA . (1996). Cancer Res., 56, 2463–2467.

  • Jones PA . (1999). Trends Genet., 15, 34–37.

  • Kee Y and Bronner-Fraser M . (2001). Mech. Dev., 109, 341–345.

  • Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J and Desprez PY . (2000). Cancer Res., 60, 1332–1340.

  • Massari ME and Murre C . (2000). Mol. Cell. Biol., 20, 429–440.

  • Moore KH, Thaler HT, Tan LK, Borgen PI and Cody III HS . (2004). Cancer, 100, 929–934.

  • Pagliuca A, Bartoli PC, Saccone S, Della Valle G and Lania L . (1995). Genomics, 27, 200–203.

  • Rivera R and Murre C . (2001). Oncogene, 20, 8308–8316.

  • Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R and Birner P . (2003). Int. J. Cancer, 104, 677–682.

  • Shan L, Yu M, Qiu C and Snyderwine EG . (2003). Am. J. Pathol., 163, 2495–2502.

  • Singh J, Murata K, Itahana Y and Desprez PY . (2002). Oncogene, 21, 1812–1822.

  • Spugnardi M, Tommasi S, Dammann R, Pfeifer GP and Hoon DS . (2003). Cancer Res., 63, 1639–1643.

  • Takeuchi H, Kuo C, Morton DL, Wang HJ and Hoon DS . (2003). Cancer Res., 63, 441–448.

  • Toyota M and Issa JP . (1999). Semin. Cancer Biol., 9, 349–357.

  • Umetani N, Fujimoto A, Takeuchi H, Shinozaki M, Bilchik AJ and Hoon DS . (2004a). Oncogene, 23, 8292–8300.

  • Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ and Hoon DS . (2004b). Clin. Cancer Res., 10, 7475–7483.

  • Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA and King MC . (2002). Proc. Natl. Acad. Sci. USA, 99, 7560–7565.

  • Zebedee Z and Hara E . (2001). Oncogene, 20, 8317–8325.

Download references

Acknowledgements

This study was supported in part by funding from the Susan Komen Breast Cancer Foundation, Gonda Foundation, US Army DOD Breast Grant, and FANY.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dave S B Hoon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Umetani, N., Mori, T., Koyanagi, K. et al. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24, 4721–4727 (2005). https://doi.org/10.1038/sj.onc.1208538

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208538

Keywords

This article is cited by

Search

Quick links